Table 3 |
|||||||
|
Cox proportional hazards analysis for overall and disease-free survival |
|||||||
| Technique |
Parameter |
Overall survival |
Disease-free survival |
||||
| HR |
95% CI |
p |
HR |
95% CI |
p |
||
|
|
|||||||
| FISH |
HER1 |
||||||
| Continuous 0.1 |
1.02 |
0.97–1.07 |
0.380 |
1.03 |
0.98–1.07 |
0.301 |
|
| Continuous 1.0 |
1.24 |
0.77–2.00 |
1.28 |
0.80–2.03 |
|||
| HER2 |
|||||||
| Continuous 0.1 |
1.02 |
1.01–1.02 |
0.001 |
1.02 |
1.01–1.03 |
<0.001 |
|
| Continuous 1.0 |
1.16 |
1.06–1.26 |
1.18 |
1.08–1.29 |
|||
| Dichotomous (≤1.5 vs. ≥1.6) |
2.07 |
1.33–3.21 |
0.001 |
2.33 |
1.48–3.68 |
<0.001 |
|
| HER3 |
|||||||
| Continuous 0.1 |
1.07 |
0.99–1.15 |
1.09 |
1.01–1.18 |
0.031 |
||
| Continuous 1.0 |
1.88 |
0.88–4.01 |
0.102 |
2.35 |
1.08–5.11 |
||
| HER4 |
|||||||
| Continuous 0.1 |
0.90 |
0.75–1.09 |
0.289 |
0.92 |
0.76–1.12 |
0.395 |
|
| Continuous 1.0 |
0.36 |
0.06–2.36 |
0.43 |
0.06–3.03 |
|||
| IHC |
HER1 |
1.66 |
0.96–2.86 |
0.070 |
1.55 |
0.87–2.77 |
0.139 |
| HER2 |
1.42 |
0.90–2.25 |
0.131 |
1.58 |
0.99–2.54 |
0.057 |
|
| HER3 |
0.84 |
0.51–1.37 |
0.484 |
0.93 |
0.55–1.56 |
0.778 |
|
| HER4 |
1.48 |
0.97–2.26 |
0.070 |
1.51 |
0.97–2.33 |
0.066 |
|
| HER2 divided |
1.72 |
1.07–2.75 |
0.024 |
1.89 |
1.16–3.08 |
0.010 |
|
| Ki-67 |
1.49 |
0.87–2.55 |
0.145 |
1.44 |
0.83–2.49 |
0.197 |
|
| ER |
0.58 |
0.37–0.91 |
0.018 |
0.59 |
0.37–0.96 |
0.031 |
|
| PR |
0.48 |
0.27–0.74 |
0.002 |
0.42 |
0.24–0.71 |
0.001 |
|
| Histology |
pT |
1.62 |
1.35–1.93 |
<0.001 |
1.72 |
1.43–2.08 |
<0.001 |
| pN |
1.98 |
1.67–2.35 |
<0.001 |
2.18 |
1.81–2.62 |
<0.001 |
|
| Grading |
2.10 |
1.54–2.87 |
<0.001 |
2.18 |
1.56–3.05 |
<0.001 |
|
|
|
|||||||
|
Hazard ratios (HR), confidence intervals and p values of investigated parameters dependent on overall and disease-free survival (CI, confidence interval with lower and upper limits). All immunohistochemical and histological parameters were used as categorical variables. FISH, fluorescence in situ hybridisation; IHC, immunohistochemistry. |
|||||||
|
Sassen et al. Breast Cancer Research 2008 10:R2 doi:10.1186/bcr1843 |
|||||||